Sio Gene Therapies to Participate in Upcoming Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/23/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY

6. BABA
7. AVGO
8. SPCX
9. NTES
10. DE

Get Alerts SIOX Hot Sheet

Price: $0.42 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.

Cantor Fitzgerald Global Healthcare Conference

Participation:	Presentation
Presenter:Date:Time: Webcast Link:	Pavan Cheruvu, MD, Chief Executive OfficerMonday, September 27th 10:00 AM EThttps://wsw.com/webcast/cantor12/siox/2117150

Chardan Genetic Medicines Conference

Participation:	Presentation
Presenter:Date:Time: Webcast Link:	Pavan Cheruvu, MD, Chief Executive OfficerTuesday, October 5th9:00 AM EThttps://wsw.com/webcast/chard9/siox/1887025

Alliance for Regenerative Medicine: Cell & Gene Meeting on the Mesa

Presenter:Date:Time:

Parag V. Meswani, PharmD, Chief Commercial OfficerOctober 12, 2021The company presentation will be available to view on-demand throughout the entirety of the conference. Please visit Cell & Gene Meeting on the Mesa for full information including registration.

About Sio Gene TherapiesSio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com.

Contacts:

Media Josephine Belluardo, Ph.D. LifeSci Communications(646) 751-4361[email protected][email protected]

Investors and AnalystsParag V. MeswaniSio Gene Therapies Inc.Chief Commercial Officer[email protected]